The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Citations
1,928 citations
Cites methods from "The 2016 World Health Organization ..."
...Indeed, the clinical and molecular work of this paper factored into evidence used by the World Health Organization (WHO) to support their 2016 diagnostic update for glioma (Louis et al., 2016)....
[...]
902 citations
773 citations
772 citations
766 citations
References
2,346 citations
"The 2016 World Health Organization ..." refers background in this paper
...It is important to recognize, however, that diffuse astrocytoma, IDH-wildtype is an uncommon diagnosis and that such cases need to be carefully evaluated to avoid misdiagnosis of lower grade lesions such as gangliogliomas; moreover, anaplastic astrocytoma, IDH-wildtype is also rare, and most such tumors will feature genetic findings highly characteristic of IDH-wildtype glioblastoma [6, 38]....
[...]
..., IDH mutation and 1p/19q codeletion status) and phenotype to diagnose these tumors results in nearly all of them being compatible with either an astrocytoma or oligodendroglioma [6, 44, 48], with only rare reports of molecularly “true” oligoastrocytomas consisting of histologically and genetically distinct astrocytic (IDH-mutant, ATRX-mutant, 1p/19q-intact) and oligodendroglial (IDH-mutant, ATRX-wildtype and 1p/19q-codeleted) tumor populations [14, 49]....
[...]
...In the setting of an anaplastic oligodendroglioma with non-diagnostic genetic results, careful evaluation for genetic features of glioblastoma may be undertaken [6]....
[...]
1,501 citations
"The 2016 World Health Organization ..." refers background in this paper
..., desmoplastic/nodular, medulloblastoma with extensive nodularity, large cell, and anaplastic) and it is now widely accepted that there are four genetic (molecular) groups of medulloblastoma: WNTactivated, SHH-activated, and the numerically designated “group 3” and “group 4” [46]....
[...]
1,362 citations
1,272 citations
"The 2016 World Health Organization ..." refers background in this paper
...Historically, the prognostic differences between WHO grade II diffuse astrocytomas and WHO grade III anaplastic astrocytomas were highly significant [31]....
[...]
884 citations
"The 2016 World Health Organization ..." refers background in this paper
...Glioblastomas are divided in the 2016 CNS WHO into (1) glioblastoma, IDH-wildtype (about 90 % of cases), which corresponds most frequently with the clinically defined primary or de novo glioblastoma and predominates in patients over 55 years of age [30]; (2) glioblastoma, IDH-mutant (about 10 % of cases), which corresponds closely to socalled secondary glioblastoma with a history of prior lower grade diffuse glioma and preferentially arises in younger patients [30] (see Table 4); and (3) glioblastoma, NOS, a diagnosis that is reserved for those tumors for which full IDH evaluation cannot be performed....
[...]